President Donald Trump announced agreements with nine major pharmaceutical companies—including Amgen, Bristol Myers Squibb, and Merck—to slash drug prices for Americans, bringing the total to 14 of the world’s top 17 drugmakers under his “most-favored-nation” pricing initiative, which ensures U.S. patients pay no more than other developed nations.
By yourNEWS Media Newsroom
WASHINGTON — President Donald Trump unveiled groundbreaking agreements with nine pharmaceutical giants—Amgen, Bristol Myers Squibb, Genentech, Merck, and five others—to lower drug prices for Americans, marking a major expansion of his “most-favored-nation” pricing policy. The deals, announced during a December 19 Oval Office ceremony, now include 14 of the world’s top 17 drug manufacturers, following earlier agreements with AstraZeneca, EMD Serono, Novo Nordisk, Lilly, and Pfizer.
“What was once considered impossible is now a reality,” a senior administration official told reporters. “This is what bold leadership delivers.”
WATCH:
A Shift in Industry Resistance
The official noted that initial pharmaceutical industry resistance has “collapsed into cooperation” as companies recognize the administration’s seriousness. “This is a flood. It’s gone from a bold policy to an industry standard in record time,” the official said.
The “most-favored-nation” pricing initiative, established by executive order in May, ensures that Americans pay the same or lower prices for drugs as patients in other developed nations.
“The days of American families subsidizing cut-rate drugs for the rest of the world are ending,” the official declared.
Immediate Impact on Medicaid and Vulnerable Patients
The new pricing structure will immediately apply to Medicaid patients, protecting *“our most vulnerable citizens,” the official said. The administration is also prioritizing reducing financial burdens that force seniors and others to skip medications, delay treatments, or accumulate medical debt.
New Federal Website and Future Savings
A new federal website, Trumprx.gov, will launch in January 2026, offering reduced prices on many prescription drugs. All future drugs in development will also be sold at most-favored-nation prices.
Economic and National Security Benefits
The agreements include over $150 billion in investments from the pharmaceutical companies, which will expand U.S. research, development, and manufacturing. “This is about rebuilding American might,” the official said, highlighting job creation and economic growth.
“It means more national security and more American independence.”
A Turning Point for Drug Pricing
Trump’s initiative represents a historic shift in U.S. drug pricing policy, ending decades of Americans paying inflated prices while other nations benefited from lower costs. With 14 of the world’s top 17 drugmakers now on board, the policy is rapidly becoming the global standard—and a major win for American patients.
Original article
Comments